News

News, blogs and stories from across the field of dementia, the work of Alzheimer’s Disease International and our members.

Featured news

Donanemab update: new Alzheimer’s disease treatment approved by the FDA

On 2 July 2024, the U.S. Food and Drug Administration (FDA) approved the marketing authorisation for Kisunla (donanemab) for adults with early symptomatic Alzheimer’s disease (AD), which includes mild cognitive impairment (MCI) or the mild dementia stage of Alzheimer’s disease.  Donanemab is the…

Published date:

Celebrating 40 years of ADI

This year, 2024 marks the 40th year of Alzheimer's Disease International and our work to secure a future that includes greater awareness of the condition, increased access to care, post-diagnostic support,and emerging treatments as well as a achieving a world without stigma. ADI invites our global community to celebrate with us on this momentous occasion with thanks to all who have been with us on this journey over four decades.

Published date:
Alzheimers Disease International (ADI) - Listing content

Dementia design 30 years behind, condition must be recognised as disability

Dementia design in built environment is 30 years behind physical disabilities movement ADI calls on governments to embed design in their national dementia responses under the Convention on the Rights for Persons with Disabilities Dementia design follows simple principles, is cost effective and dramatically improves enjoyment and safety of built environment…

Published date: